VA-HILTON-EFFECT
22.10.2020 16:02:05 CEST | Business Wire | Press release
The Hilton Effect Foundation announced today its 2020 Hilton Effect grantees, which include community-based organizations playing a direct role in COVID-19 pandemic recovery efforts. Through these grants and donations already made by the Foundation, which serves as Hilton ’s primary philanthropic arm, the Foundation has now awarded more than $1 million dollars in COVID-19 community response efforts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005724/en/
“A core part of the Hilton Effect Foundation’s work is to support our communities around the world through both good times and bad,” said Kate Mikesell, president, Hilton Effect Foundation. “From the very start of the pandemic, we have been listening to community leaders about the direct and indirect challenges they are facing as a result of COVID-19. Based on their feedback, we have focused our grants on driving inclusive recovery and strengthening community resiliency.”
The Hilton Effect Foundation’s grants aim to address some of the most urgent humanitarian needs arising from the pandemic: food security, sanitation/hygiene, economic security and clean air and water. Consistent with Hilton’s commitment to respecting human rights, driving racial equality and promoting inclusive growth for all, the Foundation prioritized organizations addressing these needs, while also directly supporting minority populations and other vulnerable communities that have been disproportionately impacted by the pandemic.
Terence Lester, executive director of grant recipient Love Beyond Walls, which works to raise awareness of societal needs and support disadvantaged individuals, including those experiencing homelessness, said, “We’re all interconnected and can help one another during challenging times. This is why it’s critical for organizations like Love Beyond Walls to join forces with the Hilton Effect Foundation in order to support local communities that have been severely impacted by the global pandemic. Together, we can make a difference and create a more equitable and inclusive world.”
The 23 grants have been awarded in the following categories:
Food Security: The United Nations World Food Programme predicts that the number of people facing acute food insecurity could nearly double this year to 265 million due to the economic fallout of COVID-19. The Foundation has awarded grants to the following organizations addressing this need:
- Food Forward (United States)
- Harvest Against Hunger (United States)
- Musubie (Japan)
- Scholars of Sustenance (Thailand)
- Wildlife and Environment Society of South Africa (South Africa)
Sanitation and Hygiene: Handwashing is the most effective way to prevent the spread of COVID-19, yet many communities around the world lack access to clean water and basic hygiene products such as soap. The Foundation has funded the following grantees that help bring water, sanitation and hygiene (WASH) practices to communities around the world and promote effective hygiene:
- Eco-Soap Bank (Africa)
- Emmanuel Foundation (Indonesia)
- Habitat for Humanity Fiji (Fiji)
- Love Beyond Walls (United States)
- Water.org (Brazil)
Economic Security: COVID-19 has had a disproportionate and devastating impact on the employment status and economic security of vulnerable populations around the world. The Foundation has funded the following organizations that are creating and providing inclusive opportunities for these populations, including training and employment programs:
- ACE Charity (Nigeria)
- BCAGlobal (United States)
- Springboard (United Kingdom)
- International Rescue Committee (Jordan)
- KARI Foundation (Australia)
- Lligam (Spain)
- My Block, My Hood, My City (United States)
Clean Air and Water: The communities that are hardest hit by racial and social injustice have also been disproportionately impacted by the climate crisis, environmental pollution and now COVID-19. The Foundation awarded grants to the following organizations to advance environmental protection, with a focus on furthering environmental justice and addressing those concerns in underserved communities:
- Ecamir (Russia)
- National Environmental Education Foundation (United States)
- Planet Water Foundation (India)
- Student Conservation Association (United States)
- The Nature Conservancy (Peru and China)
To learn more about the Hilton Effect Foundation and this year’s grantees please visit: https://hiltoneffect.org/grantees/
About Hilton Effect Foundation
The Hilton Effect Foundation is Hilton’s primary international philanthropic arm. The Foundation is a nonprofit established in the U.S. and is a registered 501(c)3 charitable organization. The Foundation awards grants, in alignment with Hilton’s Travel with Purpose 2030 Goals , that have a positive impact on travel destinations around the world. Foundation grants are awarded throughout the year in accordance with tax and legal requirements. Visit HiltonEffect.org for more information.
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,200 properties with more than 983,000 rooms, in 118 countries and territories. Dedicated to fulfilling its mission to be the world’s most hospitable company, Hilton welcomed more than 3 billion guests in its 100-year history, earned a top spot on the 2019 World’s Best Workplaces list, and was named the 2019 Global Industry Leader on the Dow Jones Sustainability Indices. In 2020, Hilton CleanStay was introduced, bringing an industry-defining standard of cleanliness and disinfection to hotels worldwide. Through the award-winning guest loyalty program Hilton Honors, the 108 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy, plus enjoy instant benefits, including digital check-in with room selection, Digital Key, and Connected Room. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005724/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
